Lung Cancer Treatment Market - By Type (Carcinoid, Non-small & Small Cell), By Therapy [(Radiation, Immunotherapy (Durvalumab), Targeted (Bevacizumab), Chemotherapy], By End-user (Hospitals, Specialty Clinics, Homecare), Global Forecast, 2023–2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationLung Cancer Treatment Market - By Type (Carcinoid, Non-small & Small Cell), By Therapy [(Radiation, Immunotherapy (Durvalumab), Targeted (Bevacizumab), Chemotherapy], By End-user (Hospitals, Specialty Clinics, Homecare), Global Forecast, 2023–2032
Lung Cancer Treatment Market Size
Lung Cancer Treatment Market size was valued at USD 15.70 billion in 2022, and it is predicted to increase at a CAGR of 12.4% from 2023 and 2032 owing to rising demand for targeted therapies and increasing incidences of lung cancer across the globe.
Lung cancer is one of the most common type of cancer and accounts for a significant number of cancer related deaths worldwide. Therefore, prevalence of lung cancer diseases is the major driver for the market. According to the International Agency for Research on Cancer's GLOBOCAN 2020 data, there were around 19.3 million new cases of cancer reported in 2020, with lungs cancer accounting for around 11.4%. The number of new cases of lung, trachea, and bronchus cancer in 2020 was estimated to be 2.21 million and is expected to reach 3.63 million by 2040.
Lung cancer was the most common cause of death in 2020, accounting for over 18% of all deaths worldwide (1.8 million). Due to the increased frequency of smoking and second-hand smoke exposure, the global incidence of lung cancer is rapidly increasing.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Lung Cancer Treatment Market Size in 2022 | USD 15.70 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 12.4% |
| 2032 Value Projection | USD 49.44 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 182 |
| Tables, Charts & Figures | 377 |
| Segments covered | Type, Therapy, End-user, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
The COVID-19 pandemic shook the world of cancer care to its core. Screenings and treatments were put on hold in many countries as hospitals were overwhelmed with COVID-19 patients. This meant that people with cancer had a harder time getting the care they needed, and they were also at higher risk of getting sick with COVID-19. On top of that, the pandemic disrupted the supply chain for cancer drugs and other supplies. This made it difficult to get the medications and equipment that cancer patients need. But as the number of COVID-19 cases has decreased, the cancer care system has started to get back on track. Screenings and treatments are starting to resume, and the supply chain is beginning to improve. This is good news for people with cancer, who are finally starting to get the care they need.
Lung Cancer Treatment Market Trends
Increasing use of combination therapy in oncology treatment is the current trend. Combination therapies involve using multiple treatments such as chemotherapy and immunotherapy, to improve outcomes in lung cancer patients. This approach has shown promising results in clinical trials and is expected to become more widely used in the coming years. For example, the combination of the chemotherapy drug cisplatin with the immunotherapy drug pembrolizumab has been shown to be effective in treating non-small cell lung cancer (NSCLC).
Lung Cancer Treatment Market Analysis
When it comes to lung cancer, there are different types to considernon-small cell lung cancer (NSCLC), small cell lung cancer, and carcinoid. Among these, NSCLC has been the most common type. One of the big reasons for NSCLC's prevalence is the availability of targeted therapies. These are drugs designed to attack specific genetic changes that help cancer cells grow and spread. They're often more effective and less harmful than traditional chemotherapy. For instance, medications like Osimertinib and crizotinib are used in targeted therapies for NSCLC patients with specific genetic mutations. These drugs have been approved to treat this type of lung cancer and have shown promising results.
According to the American Cancer Society, 236,740 lung and bronchus cancers are likely to be diagnosed in the United States in 2022, with 130,180 deaths. NSCLC is expected to account for about 85% of those cases. Hence, this is likely to create demand for lung cancer treatment over the forecast period.
The field of lung cancer treatment has various options, including radiation, immunotherapy, targeted therapy, chemotherapy, and other approaches. Among these, targeted therapy stands out as the most dominant, capturing 36.6% of the market revenue in 2022. Targeted therapy is unique because it's personalized, designed to tackle specific genetic changes in the patient's cancer cells. This approach enables doctors to tailor treatment specifically to each patient's needs, leading to better outcomes. Several targeted therapy medications have received approval for treating a specific type of lung cancer called non-small cell lung cancer (NSCLC). These drugs, such as or osimertinib, crizotinib, and alectinib, have proven effective in battling NSCLC with specific genetic mutations. As a result, the use of targeted therapy has become more widespread in clinical practice, contributing to the growth of this market segment.
Based on end-user, the lung cancer treatment market is segmented as hospitals, specialty clinics, and other end-users. The hospitals segment is anticipated to grow at 12.1% CAGR by 2032. The development of new technologies and treatments for cancer has led to increased demand for cancer care services in hospitals. Hospitals have access to advanced diagnostic tools, such as emerging technologies and genetic testing and are equipped to provide a wide range of cancer treatments, including surgery, radiation therapy chemotherapy, and immunotherapy.
Lung cancer is a serious health concern in North America, with the market for its treatment reaching a whopping $15.70 billion in 2022 alone. Experts predict that this market will grow by a steady 12.4% each year until 2032, thanks to a rising need for targeted therapies and a surge in lung cancer cases worldwide. The United States dominates this market, generating a revenue of $7.17 billion in 2022. North America's strong presence in lung cancer treatment stems from several factors, includingAn aging population more susceptible to lung cancer Ongoing advancements in technology for treating lung cancer Favorable reimbursement policies that support lung cancer treatment Overall, the prevalence of lung cancer in North America is driving a significant demand for effective treatments. This trend is likely to continue, leading to further growth in the lung cancer treatment market.
According to the American Cancer Society lung cancer is the second most common cancer in both men and women in the United States. Moreover, government in North America are investing in cancer research and treatment, which is driving the development of new therapies and treatments for lung cancer. Additionally, Government funded programs provide access to lung cancer screening and early detection programs which provide outcomes for patients with lung cancer.
Lung Cancer Treatment Market Share
Some of the major market players operating in the lung cancer treatment market are
- Merck KGaA
- ONO PHARMACEUTICAL CO., LTD.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc.
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Church & Dwight Co., Inc.
- Sun Pharmaceutical Industries Ltd.
These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.
Lung Cancer Treatment Market, Industry News
- In January 2023, Merck & Co., Inc., announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a 4 centimetres [cm]), II, or IIIA non-small cell lung cancer (NSCLC).
- In May 2021, The U.S. Food and Drug Administration (FDA) approved Lumakras (sotorasib) as the first therapy for adult non-small cell lung cancer patients who have undergone at least one prior systemic therapy and whose tumours exhibit the particular genetic mutation known as KRAS G12C. This is the first FDA-approved targeted treatment for tumours with any KRAS mutation, which accounts for around 25% of non-small cell lung cancer mutations.
Lung cancer treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By type, 2018 - 2032 (USD Million)
- Non-small cell lung cancer
- Small cell lung cancer
- Carcinoid
By Therapy, 2018 - 2032 (USD Million)
- Radiation Therapy
- External beam
- Internal beam
- Systemic
- Immunotherapy
- Durvalumab
- Nivolumab
- Atezolizumab
- Pembrolizumab
- Other immunotherapies
- Targeted Therapy
- Bevacizumab
- Dabrafenib/Trametinib
- Erlotinib hydrochloride
- Osimertinib
- Other targeted therapies
- Chemotherapy
- Other therapies
By End-user, 2018 - 2032 (USD Million)
- Hospitals
- Specialty clinics
- Homecare
- Other end-users
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy